NASDAQ
RGC

Regencell Bioscience Holdings Ltd

Drug Manufacturers-Specialty & Generic
Healthcare

Prices are adjusted according to historical splits.

Regencell Bioscience Holdings Ltd Stock Price

Vitals

Today's Low:
$14.89
Today's High:
$14.89
Open Price:
$14.89
52W Low:
$12
52W High:
$34
Prev. Close:
$14.89
Volume:
0

Company Statistics

Market Cap.:
$193.76 million
Book Value:
1.128
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
-25.23%
Return on Equity TTM:
-42.19%

Company Profile

Regencell Bioscience Holdings Ltd had its IPO on 2021-07-16 under the ticker symbol RGC.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Regencell Bioscience Holdings Ltd has a staff strength of 13 employees.

Stock update

Shares of Regencell Bioscience Holdings Ltd opened at $14.89 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $14.89 - $14.89, and closed at $14.89.

This is a 0% increase from the previous day's closing price.

A total volume of 0 shares were traded at the close of the day’s session.

In the last one week, shares of Regencell Bioscience Holdings Ltd have slipped by -9.76%.

Regencell Bioscience Holdings Ltd's Key Ratios

Regencell Bioscience Holdings Ltd has a market cap of $193.76 million, indicating a price to book ratio of 23.3405 and a price to sales ratio of 0.

In the last 12-months Regencell Bioscience Holdings Ltd’s revenue was $0 with a gross profit of $0 and an EBITDA of $-7176390. The EBITDA ratio measures Regencell Bioscience Holdings Ltd's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Regencell Bioscience Holdings Ltd’s operating margin was 0% while its return on assets stood at -25.23% with a return of equity of -42.19%.

In Q3, Regencell Bioscience Holdings Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Regencell Bioscience Holdings Ltd’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-0.55 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Regencell Bioscience Holdings Ltd’s profitability.

Regencell Bioscience Holdings Ltd stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -54.5631. Its price to sales ratio in the trailing 12-months stood at 0.

Regencell Bioscience Holdings Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$15.55 million
Total Liabilities
$0
Operating Cash Flow
$0
Capital Expenditure
$575.18 million
Dividend Payout Ratio
0%

Regencell Bioscience Holdings Ltd ended 2024 with $15.55 million in total assets and $0 in total liabilities. Its intangible assets were valued at $15.55 million while shareholder equity stood at $14.66 million.

Regencell Bioscience Holdings Ltd ended 2024 with $0 in deferred long-term liabilities, $0 in other current liabilities, in common stock, $0 in retained earnings and $0 in goodwill. Its cash balance stood at $0 and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.

Regencell Bioscience Holdings Ltd’s total current assets stands at $14.19 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $0 and inventory worth $0.

In 2024, Regencell Bioscience Holdings Ltd's operating cash flow was $0 while its capital expenditure stood at $575.18 million.

Comparatively, Regencell Bioscience Holdings Ltd paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$14.89
52-Week High
$34
52-Week Low
$12
Analyst Target Price
$

Regencell Bioscience Holdings Ltd stock is currently trading at $14.89 per share. It touched a 52-week high of $34 and a 52-week low of $34. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $17.61 and 200-day moving average was $24.66 The short ratio stood at 0.2 indicating a short percent outstanding of 0%.

Around 8876.2% of the company’s stock are held by insiders while 0.6% are held by institutions.

Frequently Asked Questions About Regencell Bioscience Holdings Ltd

The stock symbol (also called stock or share ticker) of Regencell Bioscience Holdings Ltd is RGC

The IPO of Regencell Bioscience Holdings Ltd took place on 2021-07-16

Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)

Last Price
Chg
Chg%
Bitfarms Ltd (BITF)
$1.15
0.05
+4.55%
$0.07
0
+3.19%
$0.18
0.02
+12.5%
$29.75
-0.24
-0.8%
$283.1
-4.55
-1.58%
$0.15
0
+3.37%
$446.05
-13.55
-2.95%
$768.05
-30.55
-3.83%
CARE Ratings Ltd (CARERATING)
$818
-20.4
-2.43%
$26.02
1.14
+4.58%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Address

First Commercial Building, Causeway Bay, Hong Kong